Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)Product type:GuidanceProgramme:Technology appraisal guidancePublished date: 18 December 2019
The MAGEC system for spinal lengthening in children with scoliosisStatus:In development | In consultationProgramme:Medical technologies guidanceConsultation end date: 24 June 2020Expected publication date: 15 September 2020
Babies, children and young people's experience of healthcareStatus:In developmentProgramme:NICE guidelineExpected publication date: 7 April 2021
Looked-after children and young peopleStatus:In developmentProgramme:NICE guidelineExpected publication date: 26 April 2021
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and educationStatus:In developmentProgramme:NICE guidelineExpected publication date: 12 May 2021
Social, emotional and mental wellbeing in primary and secondary educationStatus:In developmentProgramme:NICE guidelineExpected publication date: 9 November 2021
Epilepsies in children, young people and adultsStatus:In developmentProgramme:NICE guidelineExpected publication date: 16 November 2021
Self harm: assessment, management and preventing recurrenceStatus:In developmentProgramme:NICE guidelineExpected publication date: 26 January 2022
VTS-270 for treating Niemann-Pick type C1 (ID1267)Status:ProposedProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Fenfluramine for treating Dravet syndrome [ID1109]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Secukinumab for treating active enthesitis-related arthritis and juvenile psoriatic arthritis in people aged 2 to 18 [ID3738]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Omburtamab with radioactive iodine (131I) for treating relapsed neuroblastoma [ID1664]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC